RxDoctor Payments Data

Yim Ping Cheung

Adult Health · Patchogue, NYNPI 1477137214

Payments from drug & device makers

$2,861in general payments, 2019–2025

Across 73 payments — averaging $39.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$813
  • Amgen$812
  • Phathom Pharmaceuticals, Inc.$570
  • Sumitomo Pharma America, Inc.$186
  • Novo Nordisk$141
  • AstraZeneca$119
  • plus $219 from 6 others

What the payments were for

  • Food & beverage$2,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,861 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$32,663
Medicare patients
70
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab92$154,117
VascepaIcosapent Ethyl338$98,726
Diclofenac Epolamine183$95,810
JanuviaSitagliptin Phosphate93$65,908
FarxigaDapagliflozin Propanediol80$64,468
Diclofenac Sodium114$64,303
EliquisApixaban91$61,808
LinzessLinaclotide82$53,304
MyrbetriqMirabegron98$47,308
RybelsusSemaglutide33$44,009
JardianceEmpagliflozin49$43,252
CreonLipase/Protease/Amylase53$40,207
RestasisCyclosporine23$21,999
XareltoRivaroxaban28$20,740
TradjentaLinagliptin33$18,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$812$154,11792 claims
AbbVieLinzess, Creon, Restasis, Synthroid$813$118,727201 claims
AstraZenecaFarxiga, Symbicort$119$70,483105 claims
Astellas Pharma US IncMyrbetriq$20$47,30898 claims
Novo NordiskRybelsus$141$44,00933 claims
GSKShingrix, Breo Ellipta$21$24,440125 claims
Phathom Pharmaceuticals, Inc.Voquezna$570$10,91716 claims
Sumitomo Pharma America, Inc.Gemtesa$186$10,67718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →